Skip to Main Content

Author Details

Holger S??ltmann
German Cancer Research Center (DKFZ)
1993
164
47
PMIDPaper TitleJournal TitlePublished Year
37152238An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation study.Digit Health2023
34325986Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Urol Oncol2022
36551580Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer.Cancers (Basel)2022
36461127Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.Clin Epigenetics2022
36387148Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.Front Oncol2022
35205634Impact of Surgeon's Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores.Cancers (Basel)2022
35202954Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.ESMO Open2022
34164264Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.Transl Lung Cancer Res2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33485866DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.Am J Pathol2021
33669024<i>miR-449a</i> Repression Leads to Enhanced NOTCH Signaling in <i>TMPRSS2:ERG</i> Fusion Positive Prostate Cancer Cells.Cancers (Basel)2021
34876698Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.NPJ Precis Oncol2021
34830770Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer.Cancers (Basel)2021
33959513Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.Front Oncol2021
31605236Circulating MicroRNAs as Potential Biomarkers for Lung Cancer.Recent Results Cancer Res2020
32051394Correction: Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.Cell Death Dis2020
33161228Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.EBioMedicine2020
32674955Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53.Urol Oncol2020
32646965The ERG-Regulated <i>LINC00920</i> Promotes Prostate Cancer Cell Survival via the 14-3-3ε-FOXO Pathway.Mol Cancer Res2020
32280037High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.Urol Oncol2020
32272161Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study.J Thorac Oncol2020
32290637Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages.Cancers (Basel)2020
30535430Pathways regulating the expression of the immunomodulatory protein glycodelin in nonâ¿¿small cell lung cancer.Int J Oncol2019
30216696Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma.Proteomics Clin Appl2019
30230086Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.Genes Chromosomes Cancer2019
31549213The BRCA2 mutation status shapes the immune phenotype of prostate cancer.Cancer Immunol Immunother2019
31139322Defining molecular risk in ALK<sup>+</sup> NSCLC.Oncotarget2019
30899423Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer.Oncotarget2019
30350867Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.Int J Cancer2019
30669647Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.Cancers (Basel)2019
29198908Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.Urol Oncol2018
30029672Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.Genome Med2018
29887238FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.Urol Oncol2018
30200539Genome-Based Classification and Therapy of Prostate Cancer.Diagnostics (Basel)2018
30352093Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.PLoS One2018
30420756Correlation between genomic index lesions and mpMRI and <sup>68</sup>Ga-PSMA-PET/CT imaging features in primary prostate cancer.Sci Rep2018
30537516Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.Cancer Cell2018
28379479Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets.Brief Bioinform2018
29524530Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes.J Hepatol2018
29748622Genomic features of renal cell carcinoma with venous tumor thrombus.Sci Rep2018
29796302Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL.Future Sci OA2018
29086374Identification of E6/E7-Dependent MicroRNAs in HPV-Positive Cancer Cells.Methods Mol Biol2018
29205637A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Genes Chromosomes Cancer2018
27913729QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments.Nucleic Acids Res2017
28445989TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.Oncotarget2017
29088767Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.Oncotarget2017
28676659Mutations in BRCA2 and taxane resistance in prostate cancer.Sci Rep2017
28699162Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.Int J Cancer2017
27687312PARP inhibition in BRCA2-mutated prostate cancer.Ann Oncol2017
27279498Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.Sci Rep2016
  • 1 - 50 of 164

Recommended Authors

Karolina Edlund
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Career Start Year 2008
Number of shared co-authors 1
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 4
Daniel S Brewer
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Career Start Year 2003
Number of shared co-authors 8
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 0
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Emiliano Dalla
University of Udine
Career Start Year 2002
Number of shared co-authors 0
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 3
Sami Kilpinen
University of Helsinki
Career Start Year 2002
Number of shared co-authors 0
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 3
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 3
Loris De Cecco
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 2
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 3
Celine Lefebvre
The Scripps Research Institute
Career Start Year 1999
Number of shared co-authors 1
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 11
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 0
Liang Wang
H. Lee Moffitt Cancer Center
Career Start Year 1996
Number of shared co-authors 1
David Cogdell
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 1
Anamaria A Camargo
Hospital Sirio-Libanes
Career Start Year 1994
Number of shared co-authors 1
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 8
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 1
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 4
Kevin R Coombes
Medical College of Georgia
Career Start Year 1990
Number of shared co-authors 1
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 0
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 5
Jonathan R Pollack
Stanford University School of Medicine
Career Start Year 1987
Number of shared co-authors 0
Wan L Lam
British Columbia Cancer Research Institute
Career Start Year 1987
Number of shared co-authors 3
Mark A Watson
Washington University School of Medicine
Career Start Year 1987
Number of shared co-authors 1
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 11
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 8

Collaborators

Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 23
Thorsten Schlomm
Charite - University Hospital Berlin
Co-authored papers 18
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 13
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 13
Andreas Buness
Co-authored papers 13
Guido Sauter
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 10
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 9
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 9
Wolfgang Huber
Technische Universitat Munchen
Co-authored papers 8
Michal R Schweiger
Institute for Translational Epigenetics, University of Cologne
Co-authored papers 8
Holger Fr??hlich
Bonn-Aachen International Center for IT (B-IT), University of Bonn
Co-authored papers 8
Matthias Schlesner
University of Augsburg
Co-authored papers 7
Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Co-authored papers 7
Stefan Wiemann
Co-authored papers 6
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Co-authored papers 6
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 6
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 6
Marie-Laure Yaspo
Max Planck Institute for Molecular Genetics
Co-authored papers 5
Christoph Plass
German Cancer Research Center
Co-authored papers 5
Roland Eils
Berlin Institute of Health (BIH) and Charite
Co-authored papers 5
Esther Herpel
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 5
Sabine M Klauck
Co-authored papers 5
Vyacheslav Amstislavskiy
Max-Planck-Institute for Molecular Genetics
Co-authored papers 4
Vladimir Kuryshev
Heidelberg University
Co-authored papers 4
Ralf Herwig
Max Planck Institute for Molecular Genetics
Co-authored papers 4
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 4
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 4
Doreen Heckmann
University Children's Hospital
Co-authored papers 4
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 4
Daniela Schilling
Technical University of Munich (TUM)
Co-authored papers 3
Release 1.2